Danish pharmaceutical giant Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new CEO, replacing Lars Fruergaard Jørgensen. The company revised financial estimates, forecasting sales growth of between 8% and 14%, below previous expectations. The statement sent shares down 23%. The revision is due to weak expectations for sales of Wegovy and Ozempic drugs in the U.S. amid increased competition and use of compounded drugs. Doustdar, with over 30 years of experience in the company, promises to focus efforts on innovation and performance.
Sources
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Acţiunile Novo Nordisk s-au prăbuşit cu 23% după numirea unui nou CEO şi revizuirea negativă a estimărilor pentru 2025
Bursă. Business internaţional. Scădere de 20% ieri pe acţiunile Novo Nordisk, cândva cea mai valoroasă companie europeană Grupul farmaceutic danez Novo Nordisk a anunţat marţi o revizuire în scădere a estimărilor de vânzări şi profit pentru 2025, din cauza încetinirii creşterii în Statele Unite...
Acțiunile Novo Nordisk s-au prăbușit
Latest News
13:11
The Hungarian government publishes the names of tens of thousands of informers of the communist regime, in a national transparency initiative
13:03
South Korea announces record investments in artificial intelligence
12:55
Sorin Grindeanu, about the Simonis family’s baptism: “I understand the criticism from those who felt that some of these images convey an inappropriate message”
12:52
Alexander Zverev has become the world No. 1 in the ATP rankings for the first time.
12:41
Sorin Grindeanu calls for capping the allowances of the Boards of Directors of state-owned companies at the level of the average wage in the economy
See more news